Global Blood Therapeutics (GBT) Confirms FDA Approves Oxbryta for SCD
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/1/2026
- Wall Street ends lower as higher yields, rising oil prices mark shaky start to September
- Oil prices jump 4% as fresh US-Iran fighting stokes supply fears
- Two Saudi tankers struck in Strait of Hormuz Monday
- Dell again lifts annual forecasts as AI demand powers record results
- Fed’s Barr backs rate hike if inflation fails to cool, September odds hit 66%
Global Blood Therapeutics (GBT) Halted, News Pending
November 25, 2019 3:15 PM ESTGlobal Blood Therapeutics (NASDAQ: GBT) Halted, News Pending
... MoreGlobal Blood Therapeutics (GBT) received FDA approval of novel treatment to target abnormality in sickle cell disease
November 25, 2019 3:15 PM ESTToday, the U.S. Food and Drug Administration granted accelerated approval to Oxbryta (voxelotor) for the treatment of sickle cell disease (SCD) in adults and pediatric patients 12 years of age and older.
Todays approval provides additional hope to the 100,000 people in the U.S., and the more than 20 million globally, who live with this debilitating blood disorder, said Acting FDA Commissioner Adm. Brett P. Giroir, M.D. Our scientific investments have brought us to a point where we have many more tools available in the battle against sickle cell disease, which presents daily challenges for those living with it.... More
